All In Biotech

NDA 205098 · Boston

Varithena

Polidocanol · Intravenous

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Nov 25, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

42

7 Phase 3, 4 recruiting

FAERS reports

1,125

314 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 7, 2026.

VARITHENA (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. VARITHENA (polidocanol injectable foam) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. ( 1 ).

Mechanism: VARITHENA is a drug/device combination product that generates injectable foam. The injectable foam is composed of a liquid and gas phase, both of which are necessary to have its therapeutic effect. VARITHENA is intended to act as follows: (1) the foam displaces blood from the vein to be treated, and (2) the polidocanol then scleroses the endothelium. The active pharmaceutical ingredient of VARITHENA is polidocanol, a non-ionic surfactant sclerosing agent. The hydrophobic pole of the polidocanol molecule attaches to the lipid cell membrane of the venous endothelium, resulting in disruption of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VARITHENA · POLIDOCANOL 180MG/18ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VARITHENA · POLIDOCANOL 77.5MG/7.75ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Polidocanol" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • deep vein thrombosis321
  • no adverse event126
  • off label use83
  • wrong technique in product usage process78
  • pain67
  • product quality issue66
  • pain in extremity56
  • drug ineffective40
  • expired product administered40
  • skin discolouration39
  • thrombosis38
  • erythema35

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20081
20092
20111
20122
20133
20142
201520
201646
201773
201853
201971
2020106
2021195
2022100
202379
2024165
202596
2026109

Recalls

1 FDA enforcement reports for this application.

  • Sep 7, 2016 · Class III · Terminated

    Defective Delivery System: Incorrect type of syringe found in commercially distributed administration pack

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 228 on PubMed

Sponsor: Boston

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.